¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"body type"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • fruiting body
    ÀÚ½Çü
  • gastric body
    À§¸öÅë
  • geniculate body
    ¹«¸­Ã¼, ½½»óü
  • glomus body
    »ç±¸¼Òü, Å丮¼Òü
  • Heinz body hemolytic anemia
    ÇÏÀÎÃ÷¼Òü¿ëÇ÷ºóÇ÷
  • hyaline body
    À¯¸®Áú¼Òü
  • immersed body
    ¼öÁß½Ãü
  • inclusion body
    Æ÷ÇÔü, ºÀÀÔü
  • inclusion body fibromatosis
    Æ÷ÇÔü¼¶À¯Á¾Áõ, ºÀÀÔü¼¶À¯Á¾Áõ
  • intermediate body
    Áß°£¼Òü
  • interrenal body
    ÄáÆÏ»çÀÌü, ½Å°£Ã¼
  • intracellular inclusion body
    ¼¼Æ÷³»Æ÷ÇÔü, ¼¼Æ÷³»ºÀÀÔü
  • intraneuronal body
    ½Å°æ¼¼Æ÷³»¼Òü
  • intranuclear inclusion body
    ÇÙÆ÷ÇÔü, ÇÙ³»ºÀÀÔü
  • ketone body
    ÄÉÅæÃ¼
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • extraocular foreign body
    ´«¹ÛÀ̹°, ¾È¿ÜÀ̹°
  • ferromagnetic body
    °­ÀÚ¼ºÃ¼
  • ferruginous body
    öÇÔÀ¯¼Òü
  • foreign body
    À̹°, À̹°Áú
  • fruiting body
    ÀÚ½Çü
  • geniculate body
    ¹«¸­Ã¼, ½½»óü
  • glomus body
    Å丮¼Òü, »ç±¸¼Òü
  • hyaline body
    À¯¸®Áú¼Òü
  • immersed body
    ¼öÁß½Ãü
  • inclusion body
    Æ÷ÇÔü, ºÀÀÔü
  • intermediate body
    Áß°£¼Òü
  • interrenal body
    ÄáÆÏ»çÀÌü, ½Å°£Ã¼
  • intracellular inclusion body
    ¼¼Æ÷³»Æ÷ÇÔü
  • intraneuronal body
    ½Å°æ¼¼Æ÷³»¼Òü
  • intranuclear inclusion body
    ÇÙÆ÷ÇÔü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • fruiting body
    ÀÚ½Çü
  • gandy-gamna body
    °µµð-°¨³ª ¼Òü, Gandy-Gamna ¼Òü
  • geminal body =optic lobe
    ÀÌ´ëü(ì£Óßô÷).
  • geniculate body
    ½½»óü(ã£ßÒô÷).
  • geniculate body
    ½½»óü
  • glial cell body
    ¾Æ±³¼¼Æ÷ü
  • glomus body
    ±¸Ã¼, »ç±¸
  • heinz body
    ÇÏÀÎÁî¼Òü, Heinz ¼Òü
  • hematoxylin body
    Ç츶Åå½Ç¸° ¼Òü
  • herring body
    ½Å°æºÐºñ¹°ÃàÀû¼Òü
  • hirano body
    È÷¶ó³ë ¼Òü, Hirano ¼Òü
  • human counter =whole body c.
    Àü½Å°è¼öÀåÄ¡(ËøËàË­ËàËö̬).
  • hypophysis =pituitary body, p. gland
    ³úÇϼöü, Çϼöü(ù»á÷ô÷).
  • iliac body
    Àå°ñ ¸öü, Àå°ñ ü(íóÍéô÷).
  • iliac body
    Àå°ñ¸öü, Àå°ñü(íóÍéô÷).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • monocytic type
    ´ÜÇÙ±¸Çü(?Ì´).
  • muscular type of artery
    ±ÙÀ°Çüµ¿¸Æ
  • muscular type of lymphatic vessel
    ±ÙÀ°Çü¸²ÇÁ°ü
  • muscular type of vein
    ±ÙÀ°ÇüÁ¤¸Æ
  • mutation, plaque-type
    ÇöóÅ©Çü µ¹¿¬º¯ÀÌ
  • on off type
    Á¡¸êÇü(ïÇØþúþ).
  • on type
    Áß½ÉÇü.
  • onion skin type
    ¾çÆÄ²®Áú¸ð¾ç
  • organic reaction type
    ±âÁú¼º ¹ÝÀÀÇü(¡­Úãëëúþ).
  • ovulatory type
    ¹è¶õÇü
  • particle, C-type
    CÇü ÀÔÀÚ (·¹Æ®·Î¹ÙÀÌ·¯½ºÀÇ)
  • personality disorder, mixed type
    È¥ÀçÇü(ûèî¤úþ) ÀΰÝÀå¾Ö
  • personality, type A
    AÇü ÀΰÝ
  • personality, type B
    BÇü ÀΰÝ
  • phage type
    ÆÄÁöÇü
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • Body of sternum
    º¹Àå»À¸öÅë
    [¿¾ ¿ë¾î] Èä°ñü
  • Neurosensory cell body
    ½Å°æ°¨°¢¼¼Æ÷ü
    [¿¾ ¿ë¾î] ½Å°æ°¨°¢¼¼Æ÷ü
  • Nerve cell body
    ½Å°æ¼¼Æ÷ü
    [¿¾ ¿ë¾î] ½Å°æ¼¼Æ÷ü
  • Body of humerus
    À§ÆÈ»À¸öÅë
    [¿¾ ¿ë¾î] »ó¿Ï°ñü
  • Dense body
    Ä¡¹Ð¼Òü
    [¿¾ ¿ë¾î] Ä¡¹Ð¼Òü
  • Body of tongue
    Çô¸öÅë
    [¿¾ ¿ë¾î] ¼³Ã¼
  • Body
    ¸öÅë
    [¿¾ ¿ë¾î] Á¶Ã¼
  • Body
    ¾µ°³¸öÅë
    [¿¾ ¿ë¾î] ´ã³¶Ã¼
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
VSD Ventricular Septal Defect
  ? Types of VSD
    1. Subpulmonic(=...
ADT Accepted Dental Therapeutics; adenosine triphosphate; admission, discharge, transfer; agar-gel diffu...
AI-CAH autoimmune-type chronic active hepatitis
AIH amelogenesis imperfecta, hypomaturation type; American Institute of Homeopathy; artificial inseminat...
ALASH delta-aminolevulinate synthase, housekeeping type
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
DLBD Diffuse Lewy body disease
FFBM Fat-free body mass
FFM Fat-free body mass
FBGC Foreign Body Giant Cell
FB Foreign body
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • body snatching
    ½Ãü Àýµµ
    ½Ãü¸¦ ºÒ¹ýÀûÀ¸·Î ȹµæÇÏ´Â °ÍÀ» ¸»Çϸç, ƯÈ÷ ¸ÅÀåµÈ ½Ãü¸¦ ¹Ù·Î ¹¦¿¡¼­ ÆÄ³»´Â °Í.
  • body surface area
    üǥ¸éÀû
  • body surface potential mapping
    üǥ¸é ÀüÀ§µµ
  • body temperature ambient pressure satur
    ü¿Â ´ë±â¾Ð ¼öÁõ±â Æ÷È­ »óÅÂ
  • body wall
    üº®
  • body's of Arantius
    ¾Æ¶õƼ¿ì½º °áÀý
    ´ëµ¿¸ÆÆÇÀÇ °áÀý.
  • body-weight ratio
    üÁß ½ÅÀå ºñ
  • canal of foreign body of the external ear
    ¿ÜÀ̵µ À̹°
  • carotic body
    °æµ¿¸Æ ü
  • carotid body
    °æµ¿¸ÆÃ¼, °æµ¿¸Æ ¼Òü, ¸ñµ¿¸Æ ¼Òü
    1. °æµ¿¸Æµ¿ µÚ¿¡ À§Ä¡ÇÑ ¸»ÃÊ È­ÇÐ ¼ö°¨±â·Î ¼³ÀÎ ½Å°æÀ» ÅëÇØ È£Èí ÁßÃß¿Í ¿¬°áµÇ¾î ÀÖÀ¸¸ç, »ê¼ÒÀÇ °¨¼Ò¿¡ ƯÈ÷ ¿¹¹ÎÇÏ¿© »ê¼Ò ºÐ¾ÐÀÌ 30-60mmHg·Î °¨¼ÒÇÏ¸é ¸¹Àº ¼öÀÇ ÈïºÐÆÄ°¡ ¼ö°¨±â·ÎºÎÅÍ ¹ß»ýÇÏ¿© ±¸½É¼º ½Å°æÀ» ÅëÇØ¼­ È£Èí ÁßÃ߸¦ ÀÚ±ØÇÑ´Ù. 2. °æµ¿¸Æ ±âºÎ ±Ùó¿¡ À̾îÁø ¼Òü. °æµ¿¸Æ ¼Òü, °æµ¿¸Æ ±¸, °æµ¿¸Æ »ç±¸, °æµ¿¸Æ ¼±, °æµ¿¸Æ°£ ½Å°æÀý µî ¿©·¯ °¡Áö À̸§ÀÌ ÀÖ´Ù. µÎºÎ¿¡ Ç÷¾×À» º¸³»´Â ÃѰ浿¸ÆÀÌ ³», ¿Ü°æµ¿¸ÆÀ¸·Î °¥¶óÁö´Â °÷¿¡ Á¢ÇØ ÀÖÀ¸¸ç, dzºÎÇÑ ¸ð¼¼Ç÷°üÀÌ ±×¹°Ã³·³ º¸ÀÌ´Â ÇØ¸éü¿Í °°Àº ±¸Á¶ÀÌ´Ù. ºÓÀº ºûÀ» ¶ì¸ç, ½Ò¾Ë ¹Ý Á¤µµÀÇ Å©±â
  • carotid body chemorcepter
    °æµ¿¸Æ ¼Òü È­Çмö¿ëü
  • carotid body tumor
    °æµ¿¸Æ ¼Òü Á¾¾ç
  • central body
    Á᫐ ¼Òü
    À¯»çºÐ¿­ Áß¿¡ ¼º»óüÀÇ Á߽ɿ¡ ÀÖ´Â ±¸Á¶¹°.
  • chromatoid body
    ¿°»öÁú ¼Òü, À¯»ç ¿°»öÁúü
  • chromatoidal body
    À¯¿°»öü, Å©·Î¸¶Æ¾¾çü
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
deoxyribonucleases, type III site-specific <enzyme> Enzyme systems composed of two subunits and requiring ATP and magnesium for endonucleolytic activity; they do not function as atpases. They exist as complexes with modification methylases of similar specificity.
The systems recognise specific short DNA sequences and cleave a short distance, about 24 to 27 bases, away from the recognition sequence to give specific double-stranded fragments with terminal 5'-phosphates. Enzymes from different microorganisms with the same specificity are called isoschizomers.
Registry number: EC 3.1.21.5
(12 Dec 1998)
deoxyribonucleases, type II site-specific <enzyme> Enzyme systems containing a single subunit and requiring only magnesium for endonucleolytic activity. The corresponding modification methylases are separate enzymes. The systems recognise specific short DNA sequences and cleave either within, or at a short specific distance from, the recognition sequence to give specific double-stranded fragments with terminal 5'-phosphates. Enzymes from different microorganisms with the same specificity are called isoschizomers.
Registry number: EC 3.1.21.4
(12 Dec 1998)
deoxyribonucleases, type I site-specific <enzyme> Enzyme systems containing three different subunits and requiring ATP, s-adenosylmethionine, and magnesium for endonucleolytic activity to give random double-stranded fragments with terminal 5'-phosphates. They function also as DNA-dependent atpases and modification methylases, catalyzing the reactions of EC 2.1.1.72 and EC 2.1.1.73 with similar site-specificity. The systems recognise specific short DNA sequences and cleave at sites remote from the recognition sequence. Enzymes from different microorganisms with the same specificity are called isoschizomers.
Registry number: EC 3.1.21.3
(12 Dec 1998)
diabetes, type 1 Insulin dependent diabetes or juvenile diabetes.
(12 Dec 1998)
diabetes, type 2 Non-insulin dependent diabetes, adult-onset diabetes or insulin-resistant diabetes.
(12 Dec 1998)
disease, gaucher's type 1 A progressive genetic disease caused by a defect in an enzyme. The enzyme, called glucocerebrosidase, is needed to break down the chemical glucocerebroside. The enzyme defect in persons with Gaucher's disease (GD) leads to the accumulation of glucocerebroside in the spleen, liver, and lymph nodes. The most common early sign is enlargement of the spleen (located in the upper left abdomen). Other signs include low red blood cell counts (anaemia), a decrease in blood clotting cells (platelets), increased pigmentation of the skin, and a yellow fatty spot on the white of the eye (a pinguecula). Severe bone involvement can lead to pain and collapse of the bone of the hips, shoulders, and spine. The GD gene is on chromosome 1. The disease is a recessive trait. Both parents carry a GD gene and transmit it for their child with the disease. The parents' risk of a child with the disease is 1 in 4 with each pregnancy. This type of Gaucher's disease (noncerebral juvenile Gaucher's disease) is most common in Ashkenazi Jews (of European origin) and is the most common genetic disease among Jews in the United States.
(12 Dec 1998)
immunization, haemophilus influenzae type b See immunization, hib.
(12 Dec 1998)
influenza type a A common acute viral infection of the nasopharynx and respiratory tract which occurs in epidemic forms. A common cause is the Influenza a virus. Annual vaccination is recommended for those in high risk groups (health care workers, elderly and immunocompromised) for influenza infection.
Common symptoms include runny nose, fever, weakness, headache, body aches, muscle aches, nausea and back pain. Treatment of symptoms has been successful with amantadine or rimantadine.
(27 Sep 1997)
interferon type I <chemical> Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (interferon-alpha and interferon-beta).
Pharmacological action: antineoplastic agent, antiviral agents.
(12 Dec 1998)
interferon type II <chemical> The major interferon produced by mitogenically or antigenically stimulated lymphocytes. It is structurally different from type I interferon (interferon type I) and its major activity is immunoregulation. It has been implicated in the expression of class II histocompatibility antigens in cells that do not normally produce them, leading to autoimmune disease.
Pharmacological action: antineoplastic agent, antiviral agents.
Chemical name: Interferon-gamma (human lymphocyte protein moiety reduced)
(12 Dec 1998)
ocean-type fish An anadromous fish that shows no indication on its scales or other hard parts of an extended freshwater residence early in its life.
(09 Oct 1997)
Ellis type 1 glomerulonephritis An obsolete designation for glomerulonephritis presenting as acute glomerulonephritis, followed by complete recovery in most cases, or the development of rapidly progressive glomerulonephritis, or incomplete remission with persistent proteinuria and subsequent development of chronic glomerulonephritis.
Synonym: Ellis type 1 nephritis.
(05 Mar 2000)
Ellis type 1 nephritis An obsolete designation for glomerulonephritis presenting as acute glomerulonephritis, followed by complete recovery in most cases, or the development of rapidly progressive glomerulonephritis, or incomplete remission with persistent proteinuria and subsequent development of chronic glomerulonephritis.
Synonym: Ellis type 1 nephritis.
(05 Mar 2000)
Ellis type 2 glomerulonephritis An obsolete designation for glomerulonephritis which is usually not related to preceding bacterial infection; characterised by an insidious onset of the nephrotic syndrome, failure of complete remission, and eventual development of chronic renal failure. The kidneys usually show membranous glomerulonephritis.
Synonym: Ellis type 2 nephritis.
(05 Mar 2000)
Ellis type 2 nephritis An obsolete designation for glomerulonephritis which is usually not related to preceding bacterial infection; characterised by an insidious onset of the nephrotic syndrome, failure of complete remission, and eventual development of chronic renal failure. The kidneys usually show membranous glomerulonephritis.
Synonym: Ellis type 2 nephritis.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
ÅëÇÕ°Ë»ö ¿Ï·á